Batavia Biomanufacturing recently opened a new commercial-scale facility for manufacturing biopharmaceutical products in Leiden. The facility will be operational in the first half of 2025.
With this new facility the company is geared up to provide cutting-edge services, including upstream/downstream processes for drug substance production, drug product formulation, aseptic filling, and labeling & packaging. It is dedicated to accelerating the development and production of viral vaccines, viral vectors, and oncolytic viruses.
Batavia’s new 12,000 m² (130,000 sq ft) facility in Leiden will have the capacity to produce up to 300 million finished-dose vaccines annually. The building is designed with sustainability in mind, featuring circular concrete, solar panels, heat recovery, and a recyclable aluminum facade, and will achieve BREEAM* excellent certification.
This expansion is a significant step in enhancing the strategic autonomy of the Netherlands and Europe, especially in the wake of the COVID-19 pandemic, highlighting the critical need for local vaccine development and production.
* BREEAM-NL is the certification method for a sustainably built environment